Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
D609727-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $143.90 | |
D609727-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,400.90 | |
D609727-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $579.90 | |
D609727-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $2,000.90 | |
D609727-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,849.90 |
Synonyms | 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperidin-4-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one | GTPL11189 | AKOS040759914 | EX-A5817 | Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(4-piperidinyl)-2-pyridinyl)amino)- | DALP |
---|---|
Specifications & Purity | 98% |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of cyclin dependent kinase 4;Inhibitor of cyclin dependent kinase 6 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Molecular Weight | 446.54 |
---|
PubChem CID | 86279927 |
---|
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
G2408093 | Certificate of Analysis | Mar 14, 2024 | D609727 |
G2408094 | Certificate of Analysis | Mar 14, 2024 | D609727 |
G2408098 | Certificate of Analysis | Mar 14, 2024 | D609727 |
G2408099 | Certificate of Analysis | Mar 14, 2024 | D609727 |
G2408100 | Certificate of Analysis | Mar 14, 2024 | D609727 |
G2408117 | Certificate of Analysis | Mar 14, 2024 | D609727 |
G2408118 | Certificate of Analysis | Mar 14, 2024 | D609727 |
G2408119 | Certificate of Analysis | Mar 14, 2024 | D609727 |
G2408120 | Certificate of Analysis | Mar 14, 2024 | D609727 |
G2408121 | Certificate of Analysis | Mar 14, 2024 | D609727 |
Starting at $460.90
1. Wang J, Li Q, Yuan J, Wang J, Chen Z, Liu Z, Li Z, Lai Y, Gao J, Shen L. (2017) CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.. J Transl Med, 15 (1): (127). [PMID:28578693] |
2. Long F, He Y, Fu H, Li Y, Bao X, Wang Q, Wang Y, Xie C, Lou L. (2019) Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models.. Cancer Sci, 110 (4): (1420-1430). [PMID:30724426] |